Diaceutics’ Pharma Precision Medicine Readiness Report is the sixth in a series of annual reports that have the single goal of improving awareness, across key industrial and organizational stakeholders, of the embedded inefficiencies of the diagnostic ecosystem supporting Precision Medicine.
Precision Medicine Readiness Report 2019
In this Report we reflect that 20 years after HERCEPTIN® (trastuzumab) shifted our focus from one-size-fits-all therapy to targeted testing and treatment, it is now time to rethink the commercial relationship between testing and treatment. Specifically, it is time to “call time” on the siloed thinking that is denying patients access to the right tests and better treatments. We endeavor to use our experience with more than 500 therapy/diagnostic projects and the insights we’ve derived fromour real-world data regarding the impact our fragmented commercial approach is having on patients.